Gemini Therapeutics (GMTX) Competitors $60.29 +0.35 (+0.58%) As of 09/11/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsTrendsBuy This Stock GMTX vs. QGEN, BBIO, MRNA, ELAN, VRNA, ROIV, RVMD, GRFS, ABVX, and RYTMShould you be buying Gemini Therapeutics stock or one of its competitors? The main competitors of Gemini Therapeutics include QIAGEN (QGEN), BridgeBio Pharma (BBIO), Moderna (MRNA), Elanco Animal Health (ELAN), Verona Pharma PLC American Depositary Share (VRNA), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Grifols (GRFS), Abivax (ABVX), and Rhythm Pharmaceuticals (RYTM). These companies are all part of the "pharmaceutical products" industry. Gemini Therapeutics vs. Its Competitors QIAGEN BridgeBio Pharma Moderna Elanco Animal Health Verona Pharma PLC American Depositary Share Roivant Sciences Revolution Medicines Grifols Abivax Rhythm Pharmaceuticals Qiagen (NYSE:QGEN) and Gemini Therapeutics (NASDAQ:GMTX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation. Which has preferable earnings & valuation, QGEN or GMTX? Qiagen has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQiagen$1.98B5.09$83.59M$1.6926.80Gemini TherapeuticsN/AN/A-$71.87M-$1.00-60.29 Which has more volatility and risk, QGEN or GMTX? Qiagen has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500. Comparatively, Gemini Therapeutics has a beta of -0.12, meaning that its stock price is 112% less volatile than the S&P 500. Do analysts rate QGEN or GMTX? Qiagen currently has a consensus price target of $49.69, indicating a potential upside of 9.68%. Given Qiagen's stronger consensus rating and higher probable upside, equities analysts plainly believe Qiagen is more favorable than Gemini Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qiagen 0 Sell rating(s) 8 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.27Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is QGEN or GMTX more profitable? Qiagen has a net margin of 18.30% compared to Gemini Therapeutics' net margin of 0.00%. Qiagen's return on equity of 14.77% beat Gemini Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Qiagen18.30% 14.77% 8.87% Gemini Therapeutics N/A -38.78%-35.88% Do insiders and institutionals believe in QGEN or GMTX? 70.0% of Qiagen shares are owned by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are owned by institutional investors. 9.0% of Qiagen shares are owned by insiders. Comparatively, 12.9% of Gemini Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media prefer QGEN or GMTX? In the previous week, Qiagen had 14 more articles in the media than Gemini Therapeutics. MarketBeat recorded 14 mentions for Qiagen and 0 mentions for Gemini Therapeutics. Qiagen's average media sentiment score of 1.00 beat Gemini Therapeutics' score of 0.00 indicating that Qiagen is being referred to more favorably in the media. Company Overall Sentiment Qiagen Positive Gemini Therapeutics Neutral SummaryQiagen beats Gemini Therapeutics on 13 of the 15 factors compared between the two stocks. Get Gemini Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GMTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GMTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GMTX vs. The Competition Export to ExcelMetricGemini TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.61B$862.73M$5.78B$10.15BDividend YieldN/A4.84%5.69%4.61%P/E Ratio-60.291.1574.5925.92Price / SalesN/A27.04453.9085.92Price / CashN/A19.5637.0859.91Price / Book20.866.6912.156.29Net Income-$71.87M-$4.50M$3.28B$270.85M7 Day Performance0.17%8.88%0.98%3.36%1 Month Performance2.90%11.38%7.20%6.41%1 Year Performance24.31%25.47%63.06%28.26% Gemini Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GMTXGemini TherapeuticsN/A$60.29+0.6%N/A+21.0%$2.61BN/A-60.2930QGENQIAGEN4.453 of 5 stars$47.23-0.7%$49.69+5.2%+3.3%$10.50B$1.98B27.905,765Positive NewsBBIOBridgeBio Pharma4.4552 of 5 stars$53.21-2.0%$63.35+19.1%+87.9%$10.18B$221.90M-13.02400Positive NewsAnalyst ForecastMRNAModerna4.4907 of 5 stars$24.44-1.6%$42.88+75.5%-68.1%$9.50B$3.24B-3.245,800Positive NewsELANElanco Animal Health2.6335 of 5 stars$18.63-2.2%$17.33-6.9%+29.8%$9.24B$4.44B21.639,000VRNAVerona Pharma PLC American Depositary Share2.1652 of 5 stars$106.280.0%$109.00+2.6%+252.9%$9.19B$42.28M-107.3530Positive NewsROIVRoivant Sciences2.9588 of 5 stars$13.25+2.6%$16.38+23.6%+16.4%$9.04B$29.05M-18.91860News CoverageOptions VolumeRVMDRevolution Medicines4.2282 of 5 stars$40.93-0.3%$72.00+75.9%+11.0%$7.64B$11.58M-9.09250Trending NewsAnalyst ForecastAnalyst RevisionGRFSGrifols4.0191 of 5 stars$9.96-1.5%$10.30+3.4%+9.0%$6.84B$7.45B8.5123,822News CoveragePositive NewsABVXAbivax2.5871 of 5 stars$89.34-0.7%$95.14+6.5%+631.6%$6.75BN/A0.0061News CoverageEarnings ReportAnalyst ForecastShort Interest ↑Gap DownRYTMRhythm Pharmaceuticals3.246 of 5 stars$99.730.0%$101.57+1.8%+98.6%$6.62B$130.13M-33.12140Positive News Related Companies and Tools Related Companies QIAGEN Alternatives BridgeBio Pharma Alternatives Moderna Alternatives Elanco Animal Health Alternatives Verona Pharma PLC American Depositary Share Alternatives Roivant Sciences Alternatives Revolution Medicines Alternatives Grifols Alternatives Abivax Alternatives Rhythm Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GMTX) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored6-Figure Target for BTC by 2025Crypto ETF records broken – here's what’s next The biggest names in finance have built the infrastructure f...Crypto 101 Media | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredThe $17B signal no one expected…After SpaceX struck a $17 billion deal with EchoStar for a block of radio frequencies, tech analyst Jeff Brown...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gemini Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gemini Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GMTX Stock Alerts